Study S001621

A Multicenter, Randomized, Open-label Phase 3 Study Comparing the Efficacy and Safety of IBI362 Versus Semaglutide in Chinese Participants With Early Type 2 Diabetes and Obesity (DREAMS-3)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06184568
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 349
Start: 2024-02-29
Primary completion: 2025-09-17
Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Conditions: Type 2 Diabetes; Obesity
Interventions: DRUG:IBI362; DRUG:Semaglutide
Results posted: FALSE

Registered primary outcomes

Proportion of subjects who achieve composite endpoint of HbA1c <7.0% and ≥10% weight loss [Week 32]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0045743	1226-OR: Mazdutide vs. Semaglutide in Chinese Adults with Type 2 Diabetes and Obesity (DREAMS-3): A Randomised, Open-Label, Phase 3b Trial YINGYING LUO, Diabetes	2026	Randomized trial	DOI	cites ClinicalTrials.gov:NCT06184568